Clinical trial NCT01212575: A Retrospective NIS to Evaluate the Use of Seroquel XR and IR in the Clinical Practice of Outpatients With Schizophrenia
Official title: A Retrospective, Non-interventional Study to Evaluate the Use of Seroquel XR and Seroquel IR in the Clinical Practice of Outpatients With Schizophrenia
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Schizophrenia
Keywords: Mental disorder
Antipsychotic treatment
Lead sponsor: AstraZeneca
Sponsor class: INDUSTRY
First posted: 2010-09-30
Enrollment: 186
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients with a diagnosis of schizophrenia who are registered at an outpatient district psychiatric clinic

Brief summary: The primary objective of this non-interventional study is to investigate how Seroquel XR and Seroquel IR are used in the clinical practice of outpatients with schizophrenia. This will be done by a retrospective review of medical records to evaluate patients treated with Seroquel XR or Seroquel IR as primary antipsychotic treatment.


Eligibility criteria: Inclusion Criteria:

* Adults with a diagnosis of schizophrenia from a district psychiatric clinic in Denmark
* Patients who have received at least one dose of Seroquel XR or Seroquel IR during January - March 2010

Exclusion Criteria:

* Patients already participating in a clinical study during the study-period.

Primary outcomes:
measure: How Seroquel XR and Seroquel IR are used in the clinical practice of outpatients with schizophrenia
timeFrame: Month 1
measure: How Seroquel XR and Seroquel IR are used in the clinical practice of outpatients with schizophrenia
timeFrame: Month 2
measure: How Seroquel XR and Seroquel IR are used in the clinical practice of outpatients with schizophrenia
timeFrame: Month 3
Secondary outcomes:
measure: Co-morbidities of patients with schizophrenia receiving Seroquel XR and IR
timeFrame: Month 1
measure: Co-morbidities of patients with schizophrenia receiving Seroquel XR and IR
timeFrame: Month 2
measure: Co-morbidities of patients with schizophrenia receiving Seroquel XR and IR
timeFrame: Month 3
measure: Whether Seroquel XR and Seroquel IR are used to treat different types of outpatients with schizophrenia by evaluation of patient characteristics
timeFrame: Month 1
measure: Whether Seroquel XR and Seroquel IR are used to treat different types of outpatients with schizophrenia by evaluation of patient characteristics
timeFrame: Month 2
measure: Whether Seroquel XR and Seroquel IR are used to treat different types of outpatients with schizophrenia by evaluation of patient characteristics
timeFrame: Month 3
measure: The treatment sequence of Seroquel XR and Seroquel IR in the clinical practice of patients with schizophrenia by evaluation of duration, dosage, reason for treatment, and, if applicable, reason for change, with Seroquel XR and Seroquel IR
timeFrame: Month 1
measure: The treatment sequence of Seroquel XR and Seroquel IR in the clinical practice of patients with schizophrenia by evaluation of duration, dosage, reason for treatment, and, if applicable, reason for change, with Seroquel XR and Seroquel IR
timeFrame: Month 2
measure: The treatment sequence of Seroquel XR and Seroquel IR in the clinical practice of patients with schizophrenia by evaluation of duration, dosage, reason for treatment, and, if applicable, reason for change, with Seroquel XR and Seroquel IR
timeFrame: Month 3
Other outcomes:
Locations:
city: Arhus N
country: Denmark
facility: Research Site
state: Arhus
city: Arhus S
country: Denmark
facility: Research Site
state: Arhus
city: Cph NV
country: Denmark
facility: Research Site
state: Cph
city: Cph N
country: Denmark
facility: Research Site
state: Cph
city: Aabenraa
country: Denmark
facility: Research Site
city: Arhus
country: Denmark
facility: Research Site
city: Ballerup
country: Denmark
facility: Research Site
city: Esbjerg
country: Denmark
facility: Research Site
city: Haderslev
country: Denmark
facility: Research Site
city: Hillerod
country: Denmark
facility: Research Site
city: Middelfart
country: Denmark
facility: Research Site
city: Ronde
country: Denmark
facility: Research Site
city: Tonder
country: Denmark
facility: Research Site
Study officials:
affiliation: AstraZeneca Nordic-Södertälje, Sweden
name: Eva Dencker Vansvik
role: STUDY_DIRECTOR
affiliation: Skovager 2, Risskov, Denmark
name: Charlotte Emborg
role: PRINCIPAL_INVESTIGATOR
References:
citation: Emborg C, Hallerback T, Jorgensen L, Carlborg A. A retrospective study of clinical usage of quetiapine XR and quetiapine IR in outpatients with schizophrenia in Denmark. Hum Psychopharmacol. 2012 Sep;27(5):492-8. doi: 10.1002/hup.2254.